Delivering clinical research to make patients, and the NHS, better

Upper GI SSG March 2015

Research

Wendy Cook, Research Delivery Manager

dd/mm/yyyy

2

Cover

• Overview of network changes

• Overview of research activity

• Discussion re new studies for the portfolio

r

History

• April 2013• Cancer Network dissolved• SSG’s in the main stopped in Peninsula Network

• Historically Peninsula Cancer Research Network• RD&E, N Devon, S Devon, Plymouth and RCHT• 1 of 32 Cancer networks• Peninsula, a very successful network• Governed by the NCRN (National cancer research Network)

• April 2014 Research Transition

4

Transition

• 15 Local Research Networks, Nationally.• I LRN has 30 specialties• Geographical changes• Area now includes Musgrove Park and Yeovil• New name• CRN: South West Peninsula (Local Research Network)• Local governance• 1 funding stream• Funding given to Trusts in 1 block, not broken down into

cancer, diabetes, stroke etc

South West Peninsula CRN

Hospital SizeYeovil District Hospital NHS Foundation Trust

Small Acute

Taunton and Somerset NHS Foundation Trust

Medium Acute

Northern Devon Healthcare NHS Trust

Small Acute

Royal Devon and Exeter NHS Foundation Trust

Large Acute

South Devon Healthcare NHS Foundation Trust

Medium Acute

Plymouth Hospitals NHS Trust Large Acute

Royal Cornwall Hospitals NHS Trust Large Acute

6

Structure

7

Management of Division

Performance Management and portfolio development

• LPMS (EdGE) RAG review FPFV and T2T• Tracking of EOI return rates• Identification of new studies and promotion • Level 1 and level 2 studies, commercial and non commercial• Identify blocks and escalate e.g. ETC’s, supporting services• Coordinate regional team meetings/forums, workshops, share good

practice , work collaboratively• Attend national cancer research meetings• Attend SSG’s• Providing recruitment data and trials information to the SSG• Support Peer Review

 

8

Recruitment

Study OrganCommercial/non-commercial

Interventional/observational Sites

Recruitment 14/15

Recruitment 14/15 National

CANC-3482 JANUS 1: Ruxolitinib or placebo + capecitabine in pancreatic adenocarcinoma Pancreas Commercial   PHT 0 7ESPAC 4 Pancreas Non-commercial Interventional YDH 3 91        NDDH 1          PHT 1  FACING Oesophagus/stomachNon-commercial Interventional TST 1 6GO2 Oesophagus Non-commercial Interventional TST 0 79        RCHT 4          YDH 1  

NeoSCOPE: neoadjuvant- study of chemoradiotherapy in oesophageal cancer Oesophagus Non-commercial Interventional RD&E 0 0

OCCAMS: multicentre study determining predictive biomarkers and targets for oesophageal adenocarcinoma Oesophagus Non-commercial Observational PHT 25 501ORANGE II Plus Liver Non-commercial Interventional PHT 3 22

ROMIO feasibility: RCT if minially invasive or open oesophagectomy v1 Oesophagus Non-commercial Interventional PHT 25 102RTL advanced study Oesophagus Non-commercial Observational TST 1 42SIEGE   Non-commercial Interventional RCHT 0 56ST03 Stomach Non-commercial Interventional TST 5 172TACE-2 Liver Non-commercial Interventional PHT 3 57

9

New studies in set up

Add AspirinA phase III double-blind placebo-controlled randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.

EORTC 40091/BOS2Randomised Phase II trial evaluating the efficacy of FOLFOX alone, FOLFOX plus bevacizumab as perioperative treatment in patients with resectable liver metastases from wild type KRAS colorectal cancer

10

Pancreas

ID ISRCTN Acronym Title PrimStudyDesign ActiveStatus OpenToNewSites

17639 52263879PANasta

Cattell Warren versus Blumgart techniques of pancreatico-jejunostomy following pancreato duodenectomy  a double blinded multicentred trial. Interventional In Set-Up Pending NHS Permission Yes, within lead country only

18373   Radiocyst 01

A phase II multicentre trial of endoscopic ultrasound guided radiofrequency ablation of cystic tumours of the pancreas. Observational In Set-Up Pending NHS Permission Yes, within lead country only

18700   SCALOP-2

A multi-centre randomised study of induction chemotherapy followed by capecitabine (+/-nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer Interventional In Set-Up Pending NHS Permission Yes, within and outside lead country

17533   SEQTOR

Randomized open label study to compare the efficacy and safety of everolimus followed by chemotherapy with STZ -5FU upon progression or the reverse sequence, chemotherapy with STZ 5FU followed by everolimus upon progression, in advanced progressive pNETs Interventional In Set-Up Pending NHS Permission Yes, within and outside lead country

11

Division 1

• Duncan Wheatley, Clinical Specialty Lead duncan.wheatley@rcht.cornwall.nhs.uk 01872 258312

• Wendy Cook, Research Delivery Manager wcook1@nhs.net 01392 406995

• Ann Courtman, Administrator ann.courtman@nhs.net 01392 406966

• Subspecialty lead Post vacant. Please contact Duncan Wheatley if you would like to find out more information re the post

12

An invite toCancer Research Symposium

From Clinical Trials to Clinical Practice

Hosted by RD&E Jenny Forrest & Kate Scatchard, Consultant Clinical OncologistsatGipsy Hill Hotel, Exeter Friday 15th May 2015

Contact ann.courtman@nhs.net for more information on01392 406996